Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082879 | 0.88 | MAPK14 (0.47) | RAB9AL3MBTL1GAAMAOBSMN1; SMN2 | |
| SCHEMBL4138952 | 0.78 | SMN1; SMN2 (0.38) | RAB9AL3MBTL1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL4138408 | 0.76 | LMNA (0.41) | RAB9AL3MBTL1GAASMN1; SMN2MAPT | |
| SCHEMBL4073662 | 0.75 | BCHE (0.50) | RAB9AMAOBSMN1; SMN2NPC1CYP3A4 | |
| SCHEMBL3176111 | 0.73 | HCK (0.40) | RAB9AL3MBTL1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL4076195 | 0.72 | SMN1; SMN2 (0.44) | RAB9AL3MBTL1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL20396179 | 0.71 | MEN1 (0.50) | RAB9ASMN1; SMN2MAPTNPC1PKM | |
| SCHEMBL2479480 | 0.71 | NPC1 (0.45) | RAB9AL3MBTL1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL28617209 | 0.70 | PTGS1 (0.49) | RAB9AL3MBTL1GAAMAOBSMN1; SMN2 | |
| SCHEMBL4072416 | 0.70 | ALDH1A1 (0.37) | RAB9AL3MBTL1SMN1; SMN2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | RAB9A 2552/4885L3MBTL1 4004/4885GAA 1650/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | RAB9A 2581/4885L3MBTL1 4227/4885GAA 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.